Introduction N-Linked glycosylation is known to play an important role in glycoprotein biology, with implications for the folding, transport, stability, solubility and clearance rate of proteins (Aebi et al. 2010) . In viral pathogens, glycosylation is often important for entry into target cells and shielding the viral surface from host antibodies (Vigerust and Shepherd 2007) , although extensively glycosylated viruses may be more susceptible to capture by the host innate immune system .
In influenza A virus, the surface glycoprotein hemagglutinin (HA) is known to be the primary target for neutralizing antibodies (Wang et al. 2010) , in particular a set of canonical antigenic sites on the globular head of the molecule (Wiley and Skehel 1987) . The ability of influenza A to rapidly accumulate substitutions in HA is vital for its ability to escape from the immunological memory of its host, contributing to its seasonal impact on human health (World Health Organization 2009) . The N-glycosylation of HA is essential for the proper folding of the molecule (Daniels et al. 2003) and is also known to influence receptor binding avidity Abe et al. 2004; Das et al. 2011) , membrane fusion ) and the intracellular transport of HA (Gallagher et al. 1988) . Ultimately, the overall pattern of HA glycosylation is likely to represent a complex trade-off that encompasses multiple factors, including the balance between the roles of HA and those of the second surface glycoprotein, neuraminidase (NA), in receptor binding and viral release .
However, it is the potential impact of HA N-glycans in blocking the attachment of host antibodies that has received the most attention and is the subject of this paper. It has, for example, been argued that influenza H3N2 and H1N1 virions are "largely enclosed in carbohydrate" (Schulze 1997) and that most of the surface of HA has been shielded by glycans "at one time or another", although certain areas remain glycan free (Gallagher et al. 1988) . A recent review discusses the importance of glycans in "masking antigenic sites" (Tate et al. 2014 ). Yet the density of glycans on HA is much less than that on some other well-known viral glycoproteins, such as the HIV envelope protein gp120, which has a "dense glycan shield" (Pejchal et al. 2011) . The use of the words "shielding" and "masking" implies that antibodies are prevented from binding to particular HA residues, but is this really the case?
Here we focus on influenza A subtype H3N2, as this subtype has the most complete set of sequences covering the period 1968 to the present day. Experimental evidence suggests that all of the glycosylation sequons in the influenza A H3N2 strain A/Hong Kong/1/1968 are glycosylated, with glycans occurring at locations 8, 22, 38, 81, 165 and 285 in HA chain 1 (HA1) strain of H3N2, and location 154 in HA chain 2 (Wilson et al. 1981; Gallagher et al. 1988) . Investigations of strain A/ Memphis/102/1972 (Ward et al. 1980 ) and variant A/Aichi/2/ 1968 (X31) (Ward and Dopheide 1981) showed that both have high-mannose glycans at locations 165 and 285, with complex oligosaccharides at other sites. Of these, the sequon at location 81 disappeared by the time strain A/Victoria/3/1975 emerged (Verhoeyen et al. 1980) , whereas the other sequons have been retained to the present day. H3N2 has acquired several additional N-glycosylation sequons in the globular head region of HA since its emergence as a human pathogen in 1968 (Zhang et al. 2004) .
The presence of N-glycans at specific locations on the surface of HA has been shown to disrupt antibody binding (see, e.g., Skehel et al. 1984) . On the other hand, three antibodies have been shown to bind immediately adjacent to an HA glycan, suggesting that glycosylation has a much more limited shielding role than often assumed. First, in structure 3ZTJ (Corti et al. 2011 ) from the Protein Data Bank (PDB) (Berman et al. 2000) , antibody FI6v3 makes direct contact with the glycosylated Asn38 of H3N2 strain A/Aichi/2/1968. The orientation of the Asn38 glycan is significantly different to that found in the unbound form, suggesting that glycan flexibility facilitates antibody binding. Secondly, in PDB 1KEN containing an HA identical to that of H3N2 strain A/Hong Kong/1/68, there is direct contact between an antibody and both residue Asn165 and the N-glycan attached to that residue (Barbey-Martin et al. 2002) . Thirdly, the recent structure PDB 3WHE (Iba et al. 2014) has direct contacts between broadly neutralizing antibody F005-126, the Asn285 of H3N2 strain A/Aichi/2/1968 and the N-glycan attached to that site.
Recent research on the 2009 pandemic strain of H1N1 demonstrates that the role of N-glycans in shielding HA from antibodies is important, but incompletely understood. The Sa antigenic site of H1 is unglycosylated in both the 1918 and 2009 pandemic strains, but has up to three N-glycans in epidemic strains from the 1930s onward. It has been suggested that the exposure of site Sa to antibodies in the two pandemic strains together with its shielding by N-glycans in most intervening strains is an explanation for the unusual pattern of age-related immunity associated with the pandemic strain of 2009 (Xu et al. 2010) . However, antibodies have subsequently been identified that bind to the Sa site of a 1977 H1 strain that is predicted to have three N-glycosylation sites within site Sa, showing that the shielding is incomplete (Krause et al. 2011) .
The impact of N-glycan size on their protective role is also contentious. HA can contain N-glycans of varying types and sizes, including high-mannose and complex oligosaccharides (Wilson et al. 1981) . Experiments using an H7N1 strain suggest that a range of glycan sizes, including just a single N-acetylglucosamine (GlcNAc), were sufficient to prevent antibody binding to an epitope spanning the glycosylation site at 149 (Munk et al. 1992) , whereas monoglycosylated HA (with every glycan truncated to a single GlcNAc) has been associated with the exposure of conserved epitopes and increased antibody neutralizing activity (Wang et al. 2009 ). Monoglycosylated HA has since been linked to the induction of broadly neutralizing antibodies, but its efficacy is now attributed to a set of factors (including the stimulation of a stronger dendritic cell response and the induction of more CD8+ T cells), with uncertainty about the contribution from epitope exposure (Chen et al. 2014) .
In summary, it remains unclear, from existing experimental evidence, whether antibodies that bind close to N-glycans are a rare or commonplace feature of human herd immune responses to influenza A, and there is little prospect that this situation will change in the near future. The precise location of antibodies binding to wild-type strains is largely unknown and difficult to determine experimentally. Where high-resolution structural data exists, these are for antibodies of non-human origin (such as mouse BALB/c antibody HC63 in PDB 1KEN) or for broadbinding human antibodies that occur rarely, if at all, within the repertoires of most individuals (such as antibody FI6v3 in PDB 3ZTJ), and it is generally unclear whether the glycosylation state of the HA is the same as for the corresponding wild-type virus. For example, the recent PDB 3WHE structure contains an HA from H3N2 A/Aichi/2-1/1968 that was synthesized using a baculovirus expression system, such systems are increasingly capable of producing mammalian-like N-glycans, but fully humanized glycosylation is not yet possible (Toth et al. 2014) . For these reasons, it is worth considering whether computational methods can shed light on the in vivo frequency with which antibodies bind in the vicinity of HA N-glycans.
When used with appropriate caution, computational methods may enable us to infer the approximate location of an epitope in the absence of any direct experimental evidence about a corresponding antibody. Such analyses are typically based on prior knowledge of antigenic sites (Wiley and Skehel 1987) . It may be reasonable to infer, with varying degrees of certainty, that a substitution is likely to be attributable to antigenic pressure from an antibody if there is evidence of positive selection (e.g., through an analysis of synonymous and non-synonymous mutation rates) near an antigenic site (Bush et al. 1999) ; the emergence of simultaneous multiple substitutions that sweep through the viral population (Shih et al. 2007 ); a temporal relationship between a substitution and an important "antigenic transition" as identified from the analysis of antigenic data (such as hemagglutination inhibition assay data) (Smith et al. 2004) ; and/or the coordination of substitutions in both space and time (Lees et al. 2011) . The latter approach is the one adopted here, but we also take into account findings published in each of the other papers.
Several computational studies have sought to draw broad conclusions about the impact of N-glycosylation on the antigenicity of HA. Blackburne and coworkers detected no significant correlation between changes in H3 glycosylation and either changes in selective pressure or major changes in H3N2 antigenicity (Blackburne et al. 2008 ). Das and coworkers used sequence windows of 11 residues centered on predicted glycans as the basis for analyzing their potential role in shielding the canonical antigenic sites of HA from antibodies, concluding that the presence of N-glycans on H1 and H3 HAs generally reduced sequence variation at the antigenic sites where the glycans occur, but increased variation at unglycosylated antigenic sites (Das et al. 2010) . A separate analysis suggests that N-glycans located within the canonical antigenic sites of H3 have a significant role in preventing antibody binding (Kobayashi and Suzuki 2012) . This analysis depends on estimating differences in the rates of synonymous and nonsynonymous substitutions (d N /d S ) for residues within a 10 or 15 Å radius of an N-glycosylation site.
In this paper, we take a novel approach to quantify the extent to which influenza A H3 HA is effectively shielding against Limitations of influenza glycan shielding against antibodies host antibodies by glycans on the surface of HA. The key feature of our approach is the identification of a subset of substitutions in known antigen regions that are exceedingly likely to be involved in antigenic escape from host antibodies. The close proximity of such substitutions to locations that are widely accepted to be glycosylated provides evidence that glycan shielding is highly localized and suggests that host antibodies commonly bind close to glycans in vivo as an integral part of the herd immunity characteristic of the human host.
Results

Predicted N-glycosylation sites
We used NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/Net NGlyc/) to predict the location of H3N2 HA1 N-glycans for each of the 24 predominant circulating strains between 1968 and 2009. NetNGlyc predicted a total of 12 sites to be N-glycosylated in at least one of the predominant circulating strains (Supplementary data, Table SI) .
Here we focus exclusively on N-glycosylation sites located within the antigenic sites of HA. This has two key advantages: first, it is in these sites that the mutation rate attributable to antigenic pressure from bound antibodies is highest, making it easier to detect any drop in the local mutation rate attributable to the present of an N-glycan; and secondly any substitution occurring in these sites has a high probability of being attributable to antigenic pressure-either because it makes a direct contribution to antigenic drift or in compensation for a loss of fitness caused by such a substitution (Shih et al. 2007 ).
Prediction of epitope residues
We identified 29 clusters of putative epitope residues between successive predominant strains in our dataset, with each transition between successive strains having one to three such clusters associated with it, excluding BE89a to BE89b for which no cluster was found using our chosen algorithm (Lees et al. 2011) . Each cluster comprised between 3 and 11 substitutions. Using the approaches described in Materials and methods, we removed 26 reversions, three substitutions not found in antigenic sites and a further five substitutions belonging to clusters comprising fewer than three HA1 substitutions. This left us with a complete set of 132 substitutions in 27 clusters-henceforth termed epitope clusters (Supplementary data, Table SII ). The closest distance between the Cα atoms of an N-glycan attachment site and any substitution within a given epitope cluster were calculated ( Table I ). Note that, as we are conservative in our identification of epitope residues, these distances represent an upper limit on the likely distance between a bound antibody and an N-glycosylation site.
If we consider the set of epitope cluster residues that occur within 10 Å of an N-glycosylation site (Table II) , most have previously been identified as effective substitutions (i.e., substitutions that are dominant in viral samples for at least a year) that are likely to be associated with immune selection (Shih et al. 2007 ) and/or as antigenic cluster differentiators (Smith et al. 2004 ). This lends strong support to the hypothesis that these are important antigenic mutations.
Analysis of N-glycosylated site additions
In five of seven cases, the addition of an N-glycosylation site is closely associated with an epitope cluster. There are seven cases where there is a transition from non-sequon to an N-glycosylation site predicted by NetNGlyc (Supplementary data, Table SI ). Of these, three are substitutions identified as being part of epitope clusters (Supplementary data, Table SII): 126 in transition PC73-VI75, 133 in WU95-SY97 and 144 in MO99-HK02. In addition, site 276 is part of cluster BE92-JO94 that we removed from our analysis for having fewer than three HA1 substitutions. Of the remaining three N-glycosylation site additions, the emergence of site 246 in transition BK79-PH82 is only 7.1 Å from cluster residue 248; the substitution Asn to Thr at site 248 creates the sequon that enables site 246 to become glycosylated. This leaves only the addition of two N-glycans-63 in transition EN72-PC73 (34.7 Å from the nearest cluster residue) and 246 in MI85-LE86 (19.3 Å from the nearest cluster residue)-that are not closely associated with an epitope cluster.
Where the addition of an N-glycosylation site forms part of an epitope cluster, it is interesting to consider the amount of polymorphic activity in the vicinity of the site before and after it became glycosylated. Here we consider a single example in detail, location 133. The emergent N-glycosylation site 133 is located centrally within the epitope cluster in transition WU95-SY97 ( Figure 1A ), which involves a total of nine residues, the nearest being 156 (11.5 Å from 133). If we consider all available sequences, the pattern of mutations that occur in the vicinity of location 133 is consistent with a situation in which: (i) there is a progressive attempt at antigenic escape in Figure 1C) , and by the activity at nearby locations 135 at 6.3 Å from 133 ( Figure 1B ). Taken as a whole, the activity at locations close to site 133 is consistent with this interpretation (Supplemental data, Figure S1 contains the full range of data for site 133). We have undertaken a similar analysis for a second emergent N-glycosylation site that forms part of an epitope cluster, site 144. (We exclude from consideration the third such site at location 126 because it is glycosylated for all but one strain transition, HK68-EN72, and hence not amenable to this form of analysis.) The pattern of mutations that occur in the immediate vicinity of site 144 is consistent with a similar interpretation to that we have proposed above for site 133 (see Supplementary data, Figure S2 ).
Analysis of the proximity of epitopes to N-glycans Most epitope clusters are adjacent to, but do not cover, established N-glycosylation sites. Of the 27 epitope clusters between successive predominant strain transitions, 22 have at least one substitution within 15 Å of an established N-glycosylation site, 11 have at least one substitution within 10 Å, and three have at least one substitution within 5 Å (Table I and Figure 2 ; for additional clusters within 10 Å of an established N-glycosylation site, see Supplementary data, Figure S3 ).
Following the observations of Mir-Shekari and coworkers (who analyzed individual N-glycans on H1N1 strain A/WSN/ 33 using gel filtration chromatography and mass spectrometry), we might hypothesize that the size of glycans generally increases with their distance from the receptor binding site, with the exception of those at significantly buried glycosylation sites, which may be short irrespective of their location (owing to physical restrictions on oligosaccharide processing) (Mir-Shekari et al. 1997 ). However, no significant correlations between these factors and the distances of glycosylation sites from epitope cluster residues (Table I) were discernible.
Although there are documented examples of neutralizing antibodies that bind in part to N-glycans on the gp160 spike of HIV (Mouquet et al. 2012 ), we know of only two such example for influenza A HA (PDBs 1KEN and 3WHE), and one further example where there is direct contact with the HA glycan attachment Asn (PDB 3ZTJ). There is a further example of an antibody bound to an H3N2 N-glycan attached to NA (PDB 2AEP), the second surface glycoprotein of influenza A (Venkatramani et al. 2006) . In all these cases, the antibody is in direct contact with the glycan or its attachment site, but does not span it. Hence, if it is true (as we hypothesize) that an epitope cluster consists entirely of substitutions involved in antigenic escape from a single epitope (or multiple, substantially overlapping epitopes), our expectation is that such a cluster should not span an established N-glycosylation site. Of the 27 epitope clusters, two span a predicted N-glycan. In both cases, this is attributable to the inclusion within the cluster of a single outlying substitution (Supplementary data, Figure S4 ), neither of which is on our list of key cluster substitutions within 10 Å of an N-glycosylation site (Table II) . For comparison, it is worth noting that 11 clusters span N-glycan locations when they are unoccupied by N-glycans; when the duration that these locations are occupied with N-glycans is taken into account, it is apparent that unoccupied sites are more than eight times more likely than occupied sites to be spanned by our epitope clusters.
Most epitope cluster substitutions close to N-glycosylation sites are effective substitutions at locations where change is infrequent. Most of the substitutions within 10 Å of an These data were derived from Table 1 in Smith et al. (2004) , which covers the period to 2002. Strains that match a relevant predominant strain (column 1) are in bold. Substitutions having a probability >0.5 of being associated with a change in selective pressure (Blackburne et al. 2008 ) are marked with an asterisk. d Substitution 164 is also within 10 Å of N-glycosylation site 126.
e Location 126 is predicted to become an N-glycosylation site during this transition.
Limitations of influenza glycan shielding against antibodies N-glycosylation site (Table II) are effective substitutions occurring at locations where fixations are rare or uncommon. For example, there are coordinated fixations at locations 75, 131 and 155 associated with the epitope cluster from transition HK02-FU02, but there are only three other fixations at any of these locations at any time since 1968 ( Figure 3A-C) . These examples lend further support to the hypothesis that the majority of the substitutions close to N-glycosylation sites are important antigenic mutations, as it is unlikely that these locations would form part of a cluster coordinated in both time and space by chance, given the infrequency with which they mutate. One contrary example that is harder to interpret is location 124, which undergoes multiple changes over an extended period between 1979 and 2000 ( Figure 3D ), but this location is exceptional. (Graphs for the full set of substitutions in Table II are shown in Supplemental data, Figure S5 .)
Discussion
It is widely assumed that the presence of N-glycans on the surface of influenza A HA prevents the attachment of antibodies in the immediate vicinity of N-glycosylation sites. For example, in a recent paper investigating the shielding effect of the N-glycosylation of H3N2 HA, the authors analyzed the size of known HA glycans and assumed that locations within a range of 8-17 Å of an N-glycosylation site are covered by glycans that shield the molecule from the binding of antibodies, with the degree of shielding at a given site dependent on the size of glycan attached at that location (Kobayashi and Suzuki 2012) . This is clearly an oversimplification, as there are two contrary experimental examples where an antibody binds immediately adjacent to an HA glycan (Barbey-Martin et al. 2002; Corti et al. 2011) , but the in vivo prevalence of antibodies binding close to HA glycans is unknown. In this paper, we present evidence that contradicts this widely held perception that N-glycans typically shield adjacent residues over an extensive range by showing that antibodies are likely to have bound close to occupied N-glycosylation sites on the HA of subtype H3N2 on many occasions. We have done this by identifying a set of 15 substitutions that are highly likely to have arisen in response to antigenic pressure from host antibodies and that occur within 10 Å of occupied N-glycosylation sites; 11 of these substitutions are within the minimum 8 Å shielding radius proposed in Kobayashi and Suzuki (2012) , of which three are within 4 Å. All the substitutions shown here (including centrally located site 133 itself ) belong to a single epitope cluster. (B and C) The amino acid types at locations 135 and133, respectively, are shown as a percentage of all available H3 sequences (y-axis) in a given year (x-axis). In both graphs, the percentage of sequences that is believed to have a glycosylated sequon spanning location 133 is shaded. The pattern of activity at site 135 and (to a lesser extent) site 133 is striking, with polymorphic activity focused in the years immediately prior to the emergence of the N-glycan at site 133 but with negligible activity afterwards. This pattern is consistent with the hypothesis that neutralizing antibodies binding to epitopes spanning sites 133 and 135 were prevalent in the human immune response to H3N2 viruses in the period 1988-1995 and that the glycosylation of site 133 led decisively to viral escape from these antibodies.
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Although our analysis indicates that the surface area over which H3N2 HA is shielded from host antibodies by an N-glycan is much more limited than is widely assumed, this does not mean that N-glycans have a negligible antigenic role. We have shown that on the majority of occasions that a new N-glycan has arisen, it has done so within the bounds of an epitope cluster and may make a decisive contribution to antigenic escape. We also expect that an N-glycan will generally prevent an antibody from binding across its attachment site, although direct contact between an N-glycan and an antibody binding adjacent to it is possible (as demonstrated by PDB 1KEN). Thus our findings are consistent with studies that have found evidence to support the hypothesis that N-glycans located within H3 antigenic sites play an important role in preventing antibody binding (Das et al. 2010; Kobayashi and Suzuki 2012) ; where we disagree is about the assumption that physical shielding by N-glycans of adjacent residues is a necessary corollary of this hypothesis.
Materials and methods
N-Glycosylation site prediction
Putative glycosylation sites were identified within a comprehensive, curated in-house database of over 6000 influenza A H3N2 hemagglutinin HA1 sequences using the NetNGlyc 1.0 artificial neural network-based prediction software. NetNGlyc has been widely used and has a reported accuracy of 76% (http:// www.cbs.dtu.dk/services/NetNGlyc/). NetNGlyc provides two measures of prediction confidence: the average "N-glycosylation potential" score from nine artificial neural networks, and the "jury agreement" between the nine networks. A score of >0.5 is taken as a prediction that a site is occupied. A Limitations of influenza glycan shielding against antibodies prediction is deemed to be of high confidence if either the average score is >0.75 or all nine networks give an individual score of >0.5.
Sequence to structure alignments
In order to analyze the physical proximity of substitutions with respect to the predicted N-glycosylation sites, all sequences were aligned to the HA1 chain of PDB structure 1HGD for the H3N2 pandemic strain A/Aichi/2/68 using MUSCLE (Edgar 2004 ). This approach is justified by the analysis of recent H3N2 HA structures dating from 2004 to 2005, which demonstrates that the HA backbone has remained substantially unchanged since 1968 (Lin et al. 2012) . The distance between a given pair of amino acid residues is calculated as the length of the straight line between the Cα atoms of the two residues.
Identification of epitope residues
To understand the proximity with which host antibodies commonly bind to N-glycosylation sites, we needed to collect information about the epitopes of such antibodies. Given the lack of precise experimental evidence about where antibodies bind to HA as part of human herd immunity in a given season, we have used bioinformatics methods to identify residues that are highly likely to belong to epitopes on the surface of HA. Here we have erred on the cautious side to ensure that the set of residues we have identified are highly likely to be epitope residues; there are undoubtedly additional epitope residues that we do not identify (such as those associated with antibodies binding in the stalk region of HA (Lees et al. 2014) ), suggesting that we ultimately underestimate the frequency with which antibodies bind close to N-glycans.
To identify a set of high confidence epitope residues, we began by applying our earlier method for identifying residues that are strongly associated-through a temporal and spatial analysis of HA sequences-with antigenic escape (Lees et al. 2011) . A residue is deemed to be a candidate epitope residue if it belongs to a cluster of at least three substitutions occurring between successive strains and within close spatial proximity of each other, bounded by the typical diameter of a B-cell epitope, 35 Å (as derived from the analysis in Lees et al. 2011 of PDB HA-antibody complexes) . In other words, we propose that the human herd immune response around the time of the first of these strains included antibodies binding to an epitope (or overlapping epitopes) that encompassed the site of the cluster, and that the cluster of substitutions arising during the period between successive strains represents part of the virus's evasion strategy (antigenic drift) for evading those antibodies. For this Fig. 3 . The amino acid types at locations of selected cluster substitutions shown as a percentage of all available H3 sequences (y-axis) in a given year (x-axis). The percentage of sequences that is believed to have a glycosylated sequon at the relevant associated site (Table II) Table SIII) .
To further increase our confidence that our set of substitutions only contains residues that are highly likely to be associated with antigenic escape, we eliminated all substitutions occurring outside the antigenic sites of H3N2 HA. Here, we use the list of antigenic site residues presented in Lees et al. (2010) , which was derived as follows: the original sites (Wiley and Skehel 1987) were extended by Cox and coworkers to incorporate nearby residues that were variable and surface exposed on the grounds that such residues are likely to have mutated as a consequence of antigenic pressure from antibodies (Bush et al. 1999) ; subsequently, the list of residues was further extended by applying the same criteria (Bush et al. 1999 ) to a more recent set of H3N2 sequences (Lees et al. 2010) . We also removed reversions-that is, a subset of the substitutions that are more likely to be attributable to a structural preference for a particular amino acid type at a given location, rather than antigenic pressure (this analysis was undertaken using a total of 6458 sequences covering the period 1968-2011 and illustrated in Supplementary data, Figure S6 ). Having removed substitutions occurring in regions not generally considered antigenic and reversions, any remaining residues belonging to a cluster comprising fewer than three HA1 substitutions were additionally removed from further consideration.
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